Executive Summary
Syntopix Group plc is a spin-out company from the University of Leeds. Formed in 2003, Syntopix is based on the leading research of husband and wife team Drs Jon Cove and Anne Eady, both microbiologists at the University. Their work focuses on the microbiology of skin, antibiotic resistance in skin bacteria and Staphylococcus aureus as well as the pathobiology of acne and eczema. The science underpinning the Company was initially funded with ?483,000 from the Wellcome Trust, with further rounds of funding (totaling ?720,000) from the then Techtran Group, the Viking Fund and the White Rose Seedcorn Fund. This has enabled Syntopix to build a strong management team, recruit new scientific staff, extend its disease targets, relocate to new premises and expand its patent portfolio in readiness to initiate pre-clinical evaluation of its lead combinations.
Company History
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Historicals
Current Trading
Forecast Drivers and Issues
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
